Moderna’s efforts to develop next-generation vaccines faces strong headwinds
In a significant development, the U.S. Patent and Trademark Office has rejected arguments by Moderna that an Arbutus patent, known as the ‘069’ patent should be revoked since it described obvious concepts. With the news reaching the market, Moderna Inc’s shares fell by nearly 10%. Arbutus shares more than doubled to $6.20 on Nasdaq. Moderna…









